ArticleDiscovery medicine2016

Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.

Laura Spring et al.PubMed ↗Full text ↗

No numbers read from the abstract.